M. Fukuoka

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Yuichiro Ohe, Yasuo Ohashi, Kaoru Kubota et al. · Annals of Oncology · 2006 · 637 citations

Medicine, Oncology, Pharmacology +17

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

M. Fukuoka, H Niitani, Atsushi Suzuki et al. · Journal of Clinical Oncology · 1992 · 435 citations

Medicine, Oncology, Pharmacology +16

A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group.

Kiyoyuki Furuse, M. Fukuoka, H. Kato et al. · Journal of Clinical Oncology · 1993 · 284 citations

Medicine, Oncology, Pharmacology +10

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Kazuhiko Nakagawa, Tomohiro Tamura, Shunichi Negoro et al. · Annals of Oncology · 2003 · 275 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

Kenji Tamura, Isamu Okamoto, Tatsuhiko Kashii et al. · British Journal of Cancer · 2008 · 203 citations · Full text

Medicine, Oncology, Pharmacology +17